Oh I've found the green book but can't see it mentions coeliac disease.
Chronic respiratory
disease
Individuals with a severe lung condition, including those with asthma that
requires continuous or repeated use of systemic steroids or with previous
exacerbations requiring hospital admission, and chronic obstructive
pulmonary disease (COPD) including chronic bronchitis and emphysema;
bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and
bronchopulmonary dysplasia (BPD).
Chronic heart
disease and vascular
disease
Congenital heart disease, hypertension with cardiac complications, chronic
heart failure, individuals requiring regular medication and/or follow-up for
ischaemic heart disease. This includes individuals with atrial fibrillation,
peripheral vascular disease or a history of venous thromboembolism.
Chronic kidney
disease
Chronic kidney disease at stage 3, 4 or 5, chronic kidney failure, nephrotic
syndrome, kidney transplantation.
Chronic liver disease Cirrhosis, biliary atresia, chronic hepatitis.
Chronic neurological
disease
Stroke, transient ischaemic attack (TIA). Conditions in which respiratory
function may be compromised due to neurological disease (e.g. polio
syndrome sufferers). This includes individuals with cerebral palsy, severe or
profound learning disabilities, Down’s Syndrome, multiple sclerosis,
epilepsy, dementia, Parkinson’s disease, motor neurone disease and related
or similar conditions; or hereditary and degenerative disease of the
nervous system or muscles; or severe neurological disability.
Diabetes mellitus Any diabetes, including diet-controlled diabetes
Immunosuppression due to disease or treatment, including patients
undergoing chemotherapy leading to immunosuppression, patients
undergoing radical radiotherapy, solid organ transplant recipients, bone
marrow or stem cell transplant recipients, HIV infection at all stages,
multiple myeloma or genetic disorders affecting the immune system (e.g.
IRAK-4, NEMO, complement disorder, SCID).
Individuals who are receiving immunosuppressive or immunomodulating
biological therapy including, but not limited to, anti-TNF, alemtuzumab,
ofatumumab, rituximab, patients receiving protein kinase inhibitors or
PARP inhibitors, and individuals treated with steroid sparing agents such as
cyclophosphamide and mycophenolate mofetil.
Individuals treated with or likely to be treated with systemic steroids for
more than a month at a dose equivalent to prednisolone at 20mg or more
per day for adults.
Anyone with a history of haematological malignancy, including leukaemia,
lymphoma, and myeloma and those with systemic lupus erythematosus
and rheumatoid arthritis, and psoriasis who may require long term
immunosuppressive treatments.
Most of the more severely immunosuppressed individuals in this group
should already be flagged as CEV. Individuals who are not yet on the CEV
list but who are about to receive highly immunosuppressive interventions
or those whose level of immunosuppression is about to increase may be
therefore be offered vaccine alongside the CEV group, if therapy can be
safely delayed or there is sufficient time (ideally two weeks) before therapy
commences.
Some immunosuppressed patients may have a suboptimal immunological
response to the vaccine (see Immunosuppression and HIV).
Asplenia or
dysfunction of the
spleen
This also includes conditions that may lead to splenic dysfunction, such as
homozygous sickle cell disease, thalassemia major and coeliac syndrome.
Morbid obesity Adults with a Body Mass Index ≥40 kg/m².
Severe mental illness Individuals with schizophrenia or bipolar disorder, or any mental illness that
causes severe functional impairment.
Adult carers Those who are in receipt of a carer’s allowance, or those who are the main
carer of an elderly or disabled person whose welfare may be at risk if the
carer falls ill.
Younger adults in
long-stay nursing
and residential care
settings
Many younger adults in residential care settings will be eligible for
vaccination because they fall into one of the clinical risk groups above (for
example learning disabilities). Given the likely high risk of exposure in
these settings, where a high proportion of the population would be
considered eligible, vaccination of the whole resident population is
recommended.
Younger residents in care homes for the elderly will be at high risk of
exposure, and although they may be at lower risk of mortality than older
residents should not be excluded from vaccination programmes (see
priority 1 above).
For consideration of children under 16 see below